Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

• Status: Completed
• Trial end date: 2004-03-24
• Target enrollment: 0
• Participant gender: All

Summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Aprepitant; Fosaprepitant; Paroxetine

Criteria

Major Depressive Disorder